AstraZeneca (LON:AZN) Given Buy Rating at Liberum Capital
Liberum Capital reaffirmed their buy rating on shares of AstraZeneca (LON:AZN) in a research report sent to investors on Wednesday morning, ThisIsMoney.Co.Uk reports.
A number of other research analysts also recently weighed in on the company. Credit Suisse Group set a GBX 8,500 ($111.81) target price on AstraZeneca and gave the stock a buy rating in a report on Monday, February 17th. Jefferies Financial Group reiterated a hold rating and set a GBX 7,475 ($98.33) target price on shares of AstraZeneca in a report on Friday, February 14th. Deutsche Bank reiterated a buy rating on shares of AstraZeneca in a report on Thursday, March 12th. Morgan Stanley upped their target price on AstraZeneca from GBX 7,400 ($97.34) to GBX 8,100 ($106.55) and gave the stock an equal weight rating in a report on Monday, January 6th. Finally, HSBC restated a reduce rating and issued a GBX 6,235 ($82.02) price target on shares of AstraZeneca in a research note on Wednesday, November 27th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the stock. The company presently has an average rating of Buy and an average price target of GBX 7,862.14 ($103.42).
Shares of AZN stock traded down GBX 14 ($0.18) during midday trading on Wednesday, reaching GBX 6,891 ($90.65). 6,395,407 shares of the stock were exchanged, compared to its average volume of 2,310,000. AstraZeneca has a 1 year low of GBX 5,626 ($74.01) and a 1 year high of GBX 8,227.88 ($108.23). The company’s 50 day moving average is GBX 7,243.74 and its two-hundred day moving average is GBX 7,327.66. The company has a current ratio of 0.86, a quick ratio of 0.63 and a debt-to-equity ratio of 139.95. The firm has a market cap of $90.42 billion and a PE ratio of 67.16.
In related news, insider Michel Demare purchased 700 shares of the business’s stock in a transaction that occurred on Monday, February 17th. The shares were bought at an average price of GBX 7,313 ($96.20) per share, for a total transaction of £51,191 ($67,338.86).
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: Net Margin – Understanding the Different Kinds of Profit
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.